Novel aryl urea derivative

新規アリールウレア誘導体

Nouveau derive aryl-uree

Abstract

There is a need for highly effective, orally administrable FAAH inhibitors, particularly agents for the prevention and treatment of pain. Disclosed is a novel aryl urea compound represented by general formula (I), salts or solvates thereof, and pharmaceutical compositions having the same as an active ingredient. The pharmaceutical composition is primarily for use in FAAH inhibitors, and agents for pain prevention and treatment.
Selon l'invention, on a besoin d'inhibiteurs FAAH hautement efficaces, que l'on peut administrer par voie orale, en particulier des agents de prévention et de traitement de la douleur. L'invention concerne un nouveau composé d'aryl-urée représenté par la formule générale (I), des sels ou des solvates de celui-ci, ainsi que des compositions pharmaceutiques le comprenant comme principe actif. La composition pharmaceutique est essentiellement destinée à être utilisée dans des inhibiteurs FAAH, et des agents de prévention et de traitement de la douleur.
経口投与が可能であり、有効性に優れたFAAH阻害剤、とりわけ、疼痛の予防または治療剤が求められている。下記式(I)で表される新規アリールウレア化合物または塩、それらの溶媒和物、これらを有効成分とする医薬組成物。当該医薬組成物は、とりわけFAAH阻害剤、あるいは疼痛の予防または治療剤に用いられるものである。

Claims

Description

Topics

Download Full PDF Version (Non-Commercial Use)

Patent Citations (37)

    Publication numberPublication dateAssigneeTitle
    EP-0382185-A2August 16, 1990Otsuka Pharmaceutical Co., Ltd.Carbostyrilderivate
    EP-0745597-A2December 04, 1996Bristol-Myers Squibb CompanyMelatonergische Indanylpiperazine oder Homopiperazine
    JP-2002533333-AOctober 08, 2002メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング5−ht再取込み阻害剤としてのおよび5−ht1b/1d配位子としてのアミドおよび尿素誘導体
    JP-2003192673-AJuly 09, 2003Bayer Ag, バイエル アクチェンゲゼルシャフトPiperazinecarboxamide derivative
    JP-2005537247-ADecember 08, 2005シエーリング アクチエンゲゼルシャフト置換されたキノリンccr5受容体アンタゴニスト
    JP-2009501135-AJanuary 15, 2009ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプJanssen Pharmaceutica Naamloze Vennootschapアルキルキノリン及びアルキルキナゾリンのキナーゼモジュレーター
    JP-2009537473-AOctober 29, 2009エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaftアデノシンa2bレセプターアンタゴニストとしてのチアゾロ−ピラミジン/ピリジン尿素誘導体
    JP-H09249661-ASeptember 22, 1997Taiho Yakuhin Kogyo Kk, 大鵬薬品工業株式会社Oxyindole derivatite
    US-3290313-ADecember 06, 1966Searle & Co1-carbamoyl-4-xanthenylpiperazines
    WO-03037890-A2May 08, 2003Icagen, Inc.Piperidines
    WO-03084948-A1October 16, 2003Eisai Co., Ltd.Compose heterocyclique azote et medicament renfermant ce compose
    WO-2005040136-A1May 06, 2005Bristol-Myers Squibb CompanyPiperazine derivatives and their use as modulators of nuclear hormone receptor function
    WO-2005090340-A1September 29, 2005Banyu Pharmaceutical Co., Ltd.ピペリジン-1-カルボキサミド誘導体
    WO-2006054652-A1May 26, 2006Takeda Pharmaceutical Company LimitedComposé amide
    WO-2006074025-A1July 13, 2006Janssen Pharmaceutica N.V.Piperazinyl and piperidinyl ureas as modulators of fatty acid amide hydrolase
    WO-2007005510-A1January 11, 2007Janssen Pharmaceutica N.V.Urees n-heteroarylpiperazinyle en tant que modulateurs de l'hydrolase de l'amide d'acide gras
    WO-2007007069-A1January 18, 2007Vernalis (R & D) LimitedComposés azacycliques en tant qu’inhibteurs de canaux sodiques spécifiques aux neurones sensoriels
    WO-2008023720-A1February 28, 2008Astellas Pharma Inc.Urea compound or salt thereof
    WO-2009003669-A2January 08, 20094 Aza Ip NvPyrido(3,2-d)pyrimidines and pharmaceutical compositions useful for medical treatment
    WO-2009048101-A1April 16, 2009Takeda Pharmaceutical Company Limitedアミド化合物
    WO-2009127943-A1October 22, 2009Pfizer Inc.Ether benzylidene piperidine 5-membered aryl carboxamide compounds useful as faah inhibitors
    WO-2009127944-A1October 22, 2009Pfizer Inc.Ether benzylidene piperidine aryl carboxamide compounds useful as faah inhibitors
    WO-2009127946-A1October 22, 2009Pfizer Inc.Composés de 4-benzylidène-3-méthylpipéridine-aryl-carboxamide utiles comme inhibiteurs de faah
    WO-2009127948-A1October 22, 2009Pfizer Inc.Composés aryl carboxamides à 5 éléments de 4-[3-(aryloxy)benzylidène]-3-méthyl pipéridine utiles comme inhibiteurs de la faah
    WO-2009127949-A1October 22, 2009Pfizer Inc.Composés aryl carboxamides de 4-[3-(aryloxy)benzylidène]-3-méthyl pipéridine utiles comme inhibiteurs de la faah
    WO-2010009234-A1January 21, 2010Wisconsin Alumni Research FoundationMetal substrates including metal oxide nanoporous thin films and methods of making the same
    WO-2010049841-A1May 06, 2010Pfizer Inc.Composés 7-azaspiro[3.5]nonane-7-carboxamide comme modulateurs de l’hydrolase d’amides d’acides gras
    WO-2010053120-A1May 14, 2010アステラス製薬株式会社Composé de carbamate ou son sel
    WO-2010058318-A1May 27, 2010Pfizer Inc.1-oxa-8-azaspiro [4, 5 ] decane- 8 -carboxamide compounds as faah inhibitors
    WO-2010064597-A1June 10, 2010武田薬品工業株式会社Dérivé de pipéridine
    WO-2010068452-A1June 17, 2010Janssen Pharmaceutica NvModulateurs à base d’urée à substitution hétéroaryle d'amide d’acide gras hydrolase
    WO-2010068453-A1June 17, 2010Janssen Pharmaceutica NvModulateurs d'urée substitués par hétéroaryle d'amide d'acide gras hydrolase
    WO-2010117014-A1October 14, 2010武田薬品工業株式会社トリアジン誘導体
    WO-2010141809-A1December 09, 2010Janssen Pharmaceutica NvModulateurs heterocycliques a base d'uree a substitution aryle de l'hydrolase des amides d'acides gras (faah)
    WO-2010141817-A1December 09, 2010Janssen Pharmaceutica NvHeteroaryl-substituted spirocyclic diamine urea modulators of fatty acid amide hydrolase
    WO-9500240-A1January 05, 1995Cemvac System AbAppareil de preparation de ciment osseux
    WO-9814431-A1April 09, 1998Kyowa Hakko Kogyo Co., Ltd.Nitrogenous heterocyclic compounds

NO-Patent Citations (35)

    Title
    "JIKKEN KAGAKU KOZA", 1991, MARUZEN PUBLISHING CO., pages: 225 - 298
    "JIKKEN KAGAKU KOZA", 1992, MARUZEN PUBLISHING CO., pages: 187 - 243
    "JIKKEN KAGAKU KOZA", 1992, MARUZEN PUBLISHING CO., pages: 284 - 282
    "JIKKEN KAGAKU KOZA", 1992, MARUZEN PUBLISHING CO., pages: 300 - 302
    "JIKKEN KAGAKU KOZA", 1992, MARUZEN PUBLISHING CO., pages: 415 - 420
    "JIKKEN KAGAKU KOZA", 2004, MARUZEN PUBLISHING CO., pages: 327 - 352
    "JIKKEN KAGAKU KOZA", 2004, MARUZEN PUBLISHING CO., pages: 426 - 436
    "JIKKEN KAGAKU KOZA", 2004, MARUZEN PUBLISHING CO., pages: 438 - 472
    "JIKKEN KAGAKU KOZA", 30 January 2004, MARUZEN PUBLISHING CO.
    "Protective Groups In Organic Synthesis, (USA", 2006
    "SHIN-JIKKEN KAGAKU KOZA", 1977, MARUZEN PUBLISHING CO., pages: 333 - 448
    BENNETT ET AL., PAIN, vol. 33, 1988, pages 87 - 107
    BIOORG. MED. CHEM. LETT., vol. 17, 2007, pages 3287 - 3291
    BIOORGANIC & MEDICINAL CHEMISTRY, vol. 16, no. 11, 2008, pages 6124 - 6130
    BR. J. PHARMACOL., vol. 152, 2007, pages 1092 - 1101
    EUR. J. BIOCHEM., vol. 232, 1995, pages 54 - 61
    J. PHARMACOL. EXP. THER., vol. 263, 1992, pages 136 - 146
    J. PHARMACOL. EXP. THER., vol. 322, 2007, pages 236 - 242
    JOURNAL OF MEDICINAL CHEMISTRY, vol. 45, no. 2, 2002, pages 4513 - 4523
    JOURNAL OF MEDICINAL CHEMISTRY, vol. 46, no. 14, 2003, pages 2877 - 2894
    JOURNAL OF MEDICINAL CHEMISTRY, vol. 48, no. 6, 2005, pages 1857 - 1872
    LICHTMAN ET AL., J. PHARMACOL. EXP. THER., vol. 311, 2004, pages 441 - 448
    MUSTAFA A.A. ET AL., GENERAL PHARMACOLOGY, vol. 23, 1992, pages 1177 - 1182
    NAMIKI A. ET AL., BRITISH JOURNAL OF ANAESTHESIA, vol. 102, 2009, pages 251 - 258
    NATURE, vol. 346, 1990, pages 561 - 567
    NATURE, vol. 384, 1996, pages 83 - 87
    NATURE, vol. 394, 1998, pages 277 - 281
    NATURE, vol. 414, 2001, pages 209 - 212
    ORGANIC PROCESS RESEARCH & DEVELOPMENT, vol. 10, no. 4, 2006, pages 822 - 828
    POMONIS J.D. ET AL., JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 306, 2003, pages 387 - 393
    PROC. NATL. ACAD. SCI., vol. 98, 2001, pages 9371 - 9376
    SCIENCE, vol. 268, 1995, pages 1506 - 1509
    SELTZER ET AL., PAIN, vol. 43, 1990, pages 205 - 218
    TETRAHEDRON, vol. 63, no. 29, 2007, pages 6755 - 6763
    TETRAHEDRON, vol. 63, no. 52, 2007, pages 12986 - 12993

Cited By (0)

    Publication numberPublication dateAssigneeTitle